ClinicalTrials.gg
Active, not recruitingNCT02138734Updated Mar 31, 2026

A Study of Intravesical BCG in Combination With ALT-803 in Patients With Non-Muscle Invasive Bladder Cancer

A Phase 1/2 interventional study of BCG (50mg/instillation) + N-803 (400 μg/instillation) and BCG (50mg/instillation) in Non-muscle Invasive Bladder Cancer, sponsored by ImmunityBio, Inc.. Active, not recruiting at 108 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-03-31.

Sponsored by ImmunityBio, Inc. · Phase 1/2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
369
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 17 studies testing BCG Vaccine in Non-Muscle Invasive Bladder Neoplasms — 6 open to participants now, 12 under way, 5 of them phase 3. BCG Vaccine · Non-Muscle Invasive Bladder Neoplasms.

Enrollment
4th of 17
369 · median 160
Started
2014
the only one that year
Phase 1/2
4 of 17
1 open now
Primary completion
2026-09
later than 4 of 11 live
Registered
3rd of 17
by date
Lead sponsor
3 of 17
ImmunityBio, Inc.

Among the 17 studies testing BCG Vaccine in Non-Muscle Invasive Bladder Neoplasms, this one is the 4th largest by enrollment, is the only one that started in 2014, is one of 4 in phase 1/2, reaches primary completion later than 4 of the 11 other live ones, and was the 3rd registered.

Non-Muscle Invasive Bladder Neoplasms

294 studies on the registry are indexed under Non-Muscle Invasive Bladder Neoplasms; 126 are open to participants now.

Browse Non-Muscle Invasive Bladder Neoplasms studies →

Open to participants now

6 of the 17 studies testing BCG Vaccine in Non-Muscle Invasive Bladder Neoplasms are open now, in 12 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

About BCG Vaccine

BCG Vaccine: first FDA approval 1989 (N/A). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 92 Non-Muscle Invasive Bladder Neoplasms studies recruiting now, 77 (84%) set no upper age limit and 5 (5%) stop at 75 or younger; 2 take children under 18; 2 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies testing BCG Vaccine in Non-Muscle Invasive Bladder Neoplasms, or all of them as a file.
02

Study summary

This is a Phase Ib/IIb, randomized, two-cohort, open-label, multicenter study of intravesical N-803 plus BCG versus BCG alone, in BCG naïve patients with high-grade NMIBC.

Read the detailed description

The study includes a dose escalation phase (phase Ib) and an expansion phase (phase IIb).

In the phase Ib, patients will be treated with intravesical N-803 in combination with BCG. The purpose of the phase Ib portion of the study is to evaluate the safety, identify the Maximum Tolerated Dose (MTD) of N-803 and determine the Recommended Dose (RD) level of N-803 in combination with BCG for the phase IIb expansion.

In the phase IIb expansion, patients will be randomized to receive either intravesical N-803 in combination with BCG or BCG alone. Patients will be enrolled into one of two study cohorts (Cohort A and Cohort B). These will be two independent study cohorts, evaluated separately for treatment efficacy.

03

Conditions studied

  • Non-muscle Invasive Bladder Cancer

Keywords

  • antitumor
  • BCG
  • bladder cancer
  • cancer
  • immunotherapy
  • instillation
  • interleukin-15
  • intravesical
  • naive
  • non-muscle invasive
  • transitional cell carcinoma
  • ALT-803
  • N-803
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Histologic confirmation of non-muscle invasive bladder cancer of the transitional cell carcinoma high-grade subtype (mixed histology tumors allowed if transitional cell histology is predominant histology).

    1. Cohort A: confirmed CIS (with or without Ta/T1 disease); Cohort B: Histologically confirmed high-grade papillary disease (Ta/T1 only).
    2. Patients are eligible if the diagnostic was done within 3 months of treatment start and a cystoscopy demonstrating no resectable disease was done within 6 calendar weeks (inclusive of 48 days) of treatment start (residual CIS is acceptable; patients with T1 disease must undergo repeat resection if muscularis propria is not present in each biopsy sample). Patients with high-grade Ta and/or T1 disease should have complete resection before study treatment.
    3. Upper tract imaging within 6 months prior to study entry must not be suspicious for upper tract .
  2. Currently eligible for intravesical BCG therapy.
  3. Age ≥ 18 years.
  4. Performance status: performance status of 0, 1, or 2.
  5. BCG-naive disease as defined as either of the following:

    1. Have not received prior intravesical BCG; or
    2. Previously received BCG, but stopped receiving more than 3 years before date of randomization.
  6. Laboratory tests performed within 21 days of treatment start:

    1. Absolute lymphocyte count ≥ Institutional lower limit of normal
    2. (AGC/ANC) ≥ 1,000/μL
    3. ≥ 100,000/µL [Patients may be transfused to meet this requirement]
    4. ≥ 8 g/dL [Patients may be transfused to meet this requirement]
    5. Calculated (GFR*) >40 mL/min or Serum creatinine ≤ 1.5 x
    6. Total ≤ 2.0 X ULN
    7. , ALT, ALP ≤ 3.0 X ULN
  7. Adequate pulmonary function without any clinical sign of severe pulmonary dysfunction. PFT > 50% if clinically indicated by the investigator.
  8. Negative serum pregnancy test if female and of (non-childbearing is defined as greater than one year or surgically sterilized).
  9. Female participants of childbearing potential must adhere to using a medically accepted method of prior to screening and agree to continue its use during the study or be surgically sterilized (e.g., hysterectomy or tubal ligation) and males must agree to use barrier methods of birth control while on study.
  10. Provide signed and HIPPA authorization and agree to comply with all protocol-specified procedures and follow-up evaluations.

    • using the following equation to calculate the eGFR for this study: eGFR in mL/min = {(140-age in years) x (weight in kg) x F}/(serum creatinine in mg/dL x 72) Where F =1 if male; and 0.85 if female

Exclusion criteria

Exclusion Criteria

  1. Prior BCG treatment or known to BCG. Patients who have received more than a single-dose post-operative treatment of mitomycin-C or gemcitabine following the most recent screening TURBT/ are excluded.
  2. Concurrent use of other agents (not including FDA-authorized drugs for the prevention and treatment of COVID-19).
  3. History of or evidence of muscle-invasive, locally advanced, and/or extravesical bladder cancer or any other cancer within the past 5 years, except: adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, adequately treated stage 1 or 2 cancer from which the patient is currently in complete remission, or stable prostate cancer (under active surveillance or hormone control).
  4. Symptomatic congestive heart failure (CHF), (New York Heart Association) Class III or IV or other clinical signs of severe cardiac dysfunction.
  5. Severe/unstable angina pectoris, or myocardial infarction within 6 months prior to study entry.
  6. History or evidence of uncontrollable CNS disease.
  7. Known -positive.
  8. Active systemic infection requiring parenteral antibiotic therapy. All prior infections must have resolved following optimal therapy.
  9. Concurrent febrile illness, active urinary tract infection, active tuberculosis, a history of hypotension or anaphylactic reactions.
  10. Ongoing chronic systemic therapy required (>10 mg oral prednisone daily or equivalent).
  11. Women who are pregnant or nursing. Female patients of must have a negative pregnancy test and must adhere to using a medically acceptable method of prior to screening and agree to continue its use during the study and for 30 days after the last dose of study drug, or be surgically sterilized (e.g., hysterectomy or tubal ligation). Women of childbearing potential are defined as any female who has experienced menarche and who is NOT permanently sterile or . Postmenopausal is defined as 12 consecutive months with no menses without an alternative medical cause. Males must agree to use barrier methods of birth control while on study and for 90 days post last dose of study drug.
  12. Psychiatric illness/social situations that would limit compliance with study requirements.
  13. Other illness that in the opinion of the investigator would exclude the patient from participating in this study.
Terms in these criteria, in plain language(23)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
369 participants (actual)

Study arms

  • Experimental
    N-803+BCG

    (Phase Ib and IIb) for BCG-naive patients

    Biological: BCG (50mg/instillation) + N-803 (400 μg/instillation)

  • Active comparator
    BCG alone

    (Phase IIb) for BCG-naive patients

    Biological: BCG (50mg/instillation)

Interventions

  • BiologicalBCG (50mg/instillation) + N-803 (400 μg/instillation)

    Drug pages: BCG Vaccine · Nogapendekin alfa inbakicept

    BCG and N-803 will be mixed together (with saline) and administered via intravesical instillation weekly for 6 consecutive weeks for induction. Phase IIb includes maintenance treatment consisting of BCG+N-803 for 3 consecutive weeks at 3, 6, 12, 18, 24, 30 and 36 months. An additional 6-week re-induction of BCG+N-803 for patients with eligible disease at 3 months in phase IIb is included.

  • BiologicalBCG (50mg/instillation)

    Drug page: BCG Vaccine

    BCG will be administered via intravesical instillation weekly for 6 consecutive weeks for induction. Phase IIb includes maintenance treatment consisting of BCG for 3 consecutive weeks at 3, 6, 12, 18, 24, 30 and 36 months. An additional 6-week re-induction of BCG for patients with eligible disease at 3 months in phase IIb is included.

06

What researchers measure

Primary outcomes

  1. Complete Response (CR) Rate

    Patients in Cohort A: compare complete response rate between treatment arms using cystoscopy, confirmatory bladder biopsy and urine cytology.

    Time frame: 6 Months

  2. Disease Free Survival (DFS)

    Patients in Cohort B: compare disease-free survival between treatment arms using cystoscopy, confirmatory bladder biopsy and urine cytology.

    Time frame: 13 Years and 3 Months

Secondary outcomes

  1. Progression-free survival (PFS)

    For phase IIb, Cohorts A \& B: Time from randomization to disease progression or death.

    Time frame: 13 Years and 3 Months

  2. Overall survival

    Time from randomization to death resulting from any cause to determine survival.

    Time frame: 13 Years and 3 months

  3. Disease specific survival

    For phase IIb, Cohorts A \& B: Time from randomization to death resulting from bladder cancer.

    Time frame: 13 Years and 3 months

  4. Time to disease worsening

    For phase IIb, Cohorts A \& B: Cystectomy or change in therapy indicative of more advanced disease, including systemic chemotherapy or radiation therapy.

    Time frame: 13 Years and 3 Months

  5. Cystectomy Free Rate

    Cystectomy-free rate will be calculated for each treatment group as the ratio of the number of subjects who don't have documented cystectomy in the database divided by the number of subjects in the ITT (Intent to treat) population.

    Time frame: 13 years and 3 months

  6. Safety Profile: Number and severity of treatment emergent AEs [Time Frame: 39 Months]

    For phase Ib and phase IIb: Number of participants with TEAEs as assessed by CTCAE v4.03.

    Time frame: 39 Months

  7. Duration of Complete Response

    To assess the duration of CR of patients treated with N-803 plus BCG compared to patients treated with BCG alone.

    Time frame: 13 Years and 3 months

  8. Complete Response Rate( All Recurrent Bladder Cancer Including Low Grade Ta Disease)

    To assess the CR rate (all recurrent bladder cancer including low grade Ta disease) of patients treated with N-803 plus BCG compared to patients treated with BCG alone.

    Time frame: 13 Years and 3 months

  9. Long Term Complete Response Rate

    To assess the long-term CR rate (as determined by the Investigator) following completion of QUILT-2.005 phase 2b.

    Time frame: 13 years and 3 Months

  10. Duration of Complete Response ( All Recurrent Bladder Cancer Including Low Grade Ta Disease)

    Time from the date of first CR (All Recurrent bladder cancer including low grade Ta Disease) to the date of evidence that the subject no longer meets the definition for CR.

    Time frame: 13 Years and 3 months

  11. Cohort B: Disease Free Survival Rate

    To assess DFS rate at 12, 18, 24, 30, and 36 months. The time from randomization until recurrence of high-grade Ta (excluding low grade Ta) or any grade T1, CIS, disease progression, cystectomy, change in therapy indicative of more advance disease or death (any cause), whichever occurs first.

    Time frame: 36 Months

  12. Cohort B: Disease Free Survival

    DFS was assessed in the following groups: 1\) All recurrent bladder cancer, including low grade Ta disease the time from randomization until recurrence of any grade Ta (including low grade Ta) or any grade T1, CIS, disease progression, cystectomy, change in therapy indicative of more advanced disease, or death (any cause), whichever occurs first 2) Patients who have high-grade Ta, low-grade T1, or CIS at 3-months and received re-induction, and have no evidence of \> low-grade Ta disease at 6-months will be considered disease-free from randomization until a second recurrence \> low-grade Ta 3) Patients who have high-grade Ta, low-grade T1, or CIS at 3-months and received re-induction, and have no evidence of any disease (including low grade Ta) at 6-months will be considered disease-free from randomization until a second recurrence ≥ low grade Ta.

    Time frame: 13 Years and 3 Months

  13. Vital signs and clinical laboratory assessment

    Vital signs include heart rate, systolic and diastolic blood pressures, respiration rate, and body temperature. Labs include the following: complete blood count with differential, complete metabolic panel, and urinalysis.

    Time frame: 36 Months

  14. Long Term Follow Up(LTFU) data from subjects who were treated

    Yearly collection of LTFU data, which includes the following: survival status, bladder cancer status (high or low grade), cystoscopy results including number of cystoscopies done for each subject, biopsy results, upper tract evaluations, posttherapies and responses and outcomes of posttherapies, urine cytology results, and other medical history or treatments, if available, related to bladder cancer.

    Time frame: 10 Years after treatment period visits

Other outcomes

  1. Exploratory Endpoints- Immunogenicity: Serum level of anti-N-803 in patient samples

    For phase Ib and IIb Measures the serum level of anti-N-803 in patient samples.

    Time frame: 36 Months

  2. Quality of Life Endpoint

    Quality of Life (QoL) as assessed by the European Organization for Research and Treatment of Cancer (EORTC) questionnaires for patients with cancer (QLQ-C30) and for patients with NMIBC (QLQ-NMIBC24).

    Time frame: 39 Months

  3. Exploratory Endpoints- Whole Slide Images (Baseline and any on-study biopsy)

    For Phase IIb

    Time frame: 39 Months

07

Study locations

108 sites

Showing the first 100 of 108 sites across 3 countries. Choose a country and city above to see the rest.

08

References and documents

Publications

  • Chamie K, Chang SS, Rosser CJ, Kramolowski E, Gonzalgo ML, Sexton WJ, Spilman P, Sender L, Reddy S, Soon-Shiong P. N-803 Plus BCG Treatment for BCG-Naive or -Unresponsive Non-Muscle Invasive Bladder Cancer: A Plain Language Review. Future Oncol. 2024;20(31):2307-2317. doi: 10.1080/14796694.2024.2363744. Epub 2024 Jul 2. PubMed 38953850 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jul 2014 (actual). Primary completion is estimated for Sep 2026, 146 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
May 13, 2014
First posted
May 15, 2014
StartActual
Jul 21, 2014
Primary completionEst.
Sep 30, 2026
CompletionEst.
Mar 4, 2039
Last update
Mar 31, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 31, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02138734
Lead sponsor
ImmunityBio, Inc.
Responsible party
Sponsor
First posted
May 15, 2014
Start date
Jul 21, 2014
Primary completion
Sep 30, 2026 (estimated)
Completion
Mar 4, 2039 (estimated)
Last update
Mar 31, 2026

Study contacts

Bobby Reddy, MD
study director · ImmunityBio, Inc.

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: BCG Vaccine · Nogapendekin alfa inbakicept

Start the discussion